Citation

Meshkat S, Rosenblat JD, Ho RC, Rhee TG, Cao B, Ceban F, Danayan K, Chisamore N, Vincenzo JDD, McIntyre RS. Psychiatry Res. 2022; 317: e114911.

Copyright

(Copyright © 2022, Elsevier Publishing)

DOI

10.1016/j.psychres.2022.114911

PMID

37732856

Abstract

Pediatric depression is a common psychiatric disorder that is associated with significant morbidity and mortality. Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist with demonstrated antidepressant effects in the adult population, however, the efficacy and safety of ketamine for the treatment of pediatric depression remains poorly understood. Electronic databases were searched from inception to June 2022 to identify relevant articles. Six articles involving 46 participants with a mean age of 15.7 years were included in this systematic review. Out of six articles, three were case reports, one was a randomized clinical trial (RCT) and two were open-label trials. All studies used 0.5 mg/kg intravenous ketamine except for one, which used 2-7 micrograms/kg. Ketamine was significantly associated with reduced depressive symptoms without severe adverse events. Taken together, the results of these studies demonstrated the potential role of ketamine for treating pediatric depression. Several important limitations were identified, most notably the small sample sizes of the component studies, and that all studies administered intravenous ketamine. Further studies with larger sample sizes and different administration modalities are needed to better determine the efficacy and safety of ketamine in pediatric depression.

Language: en

Keywords

Adolescent; Adult; Child; Humans; Pediatric; Randomized Controlled Trials as Topic; Depression; Ketamine; Databases, Factual; *Ketamine/pharmacology/therapeutic use; *Mental Disorders; Antidepressant; Bipolar disorder; Depression/drug therapy; Glutamate; Mood disorders; NMDA; Rapid acting; Sample Size